CoChat

Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects

Open access

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Abstract

Mutant isoforms of the KIT or PDGF receptors expressed by gastrointestinal stromal tumors (GISTs) are considered the therapeutic targets for STI571 (imatinib mesylate; Gleevec), a specific inhibitor of these tyrosine kinase receptors.Case reports of clinical efficacy of Gleevec in GISTs lacking the typical receptor mutations prompted a search for an alternate mode of action.Here we show that Gleevec can act on host DCs to promote NK cell activation.DC-mediated NK cell activation was triggered in vitro and in vivo by treatment of DCs with Gleevec as well as by a loss-of-function mutation of KIT.Therefore, tumors that are refractory to the antiproliferative effects of Gleevec in vitro responded to Gleevec in vivo in an NK cell-dependent manner.Longitudinal studies of Gleevec-treated GIST patients revealed a therapy-induced increase in IFN-γ production by NK cells, correlating with an enhanced antitumor response.These data point to a novel mode of antitumor action for Gleevec.Nonstandard abbreviations used: bi-injection daily (bid); bone marrow-derived DC (BM-DC); break point cluster region/Abelson leukemia virus (BCR/ABL); chronic myelogenous leukemia (CML); c-kit loss-of-function mutation (W/Wv); fms-like tyrosine 3 kinase ligand (FL); gastrointestinal stromal tumor (GIST); progression-free survival (PFS); stem cell factor (SCF); transporter associated with antigen processing (TAP).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci21102

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 35 references

Research works printed but not linked: 1

  1. Van Glabbeke, M.M., et al. 2003. Prognostic factors of toxicity and efficacy in patients with gastro-intes- tinal stromal tumors (GIST) treated with imatinib: A study of the EORTC-STBSG, ISG and AGITG [abstract]. Proc. Am. Soc. Clin. Oncol. 22:3286.

Cited by

Items 101–200 of 302

Metadata

Authors
Borg, C., Terme, M., Taïeb, J., Ménard, C., Flament, C., Robert, C., Maruyama, K., Wakasugi, H., Angevin, E., Thielemans, K., Cesne, A. L., Chung-Scott, V., Lazar, V., Tchou, I., Crépineau, F., Lemoine, F., Bernard, J., Fletcher, J. A., Turhan, A., Blay, J.-Y., Spatz, A., Emile, J.-F., Heinrich, M. C., Mécheri, S., Tursz, T., & Zitvogel, L.
Affiliations
  • Inserm (FR)
  • National Cancer Centre Japan (JP)
  • Vrije Universiteit Brussel (BE)
  • Institut Gustave Roussy (FR)
  • Institut Jean Godinot (FR)
  • Harvard University (US)
  • Hospices Civils de Lyon (FR)
  • Assistance Publique – Hôpitaux de Paris (FR)
  • Oregon Health & Science University (US)
Corresponding author
Zitvogel, Laurence
Venue
Journal of Clinical Investigation
Published
2004-08-01
Volume
114
Issue
3
Pages
379-388
ISSN
0021-9738 (ISSN-L)
OpenAlex
W2161785083
Cited by
302
References
35
Citations by year
2026: 5 · 2025: 1 · 2024: 4 · 2023: 3 · 2022: 11 · 2021: 8 · 2020: 13 · 2019: 9 · 2018: 4 · 2017: 11 · 2016: 14 · 2015: 19 · 2014: 16 · 2013: 24 · 2012: 19
FWCI
16.77
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Investigation (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
  • VUBIR (Vrije Universiteit Brussel) (submittedVersion)
Funders
  • Novartis Pharmaceuticals Corporation
  • Institut National de la Santé et de la Recherche Médicale
  • Hospices Civils de Lyon
Topics
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal Tumor Research and Treatment
  • Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
  • Life Sciences › Immunology and Microbiology › Immunology › Mast cells and histamine
Keywords
imatinib mesylate, gastrointestinal stromal tumor, NK cell activation, dendritic cells, interferon-gamma, antitumor immunity, PDGF receptor, stem cell factor
MeSH terms
Imatinib Mesylate, Animals, Antineoplastic Agents, Benzamides, Dendritic Cells, Enzyme Inhibitors, Female, Gastrointestinal Neoplasms, Humans, Interferon-gamma, Killer Cells, Natural, Leukocytes, Mononuclear, Longitudinal Studies, Mice, Inbred C57BL, Mutation, Piperazines, Protein-Tyrosine Kinases, Pyrimidines, Gene Expression Regulation, Neoplastic, Case-Control Studies, Mice, SCID, Stromal Cells, Receptors, Platelet-Derived Growth Factor, Mice, Knockout, Neutrophil Activation, Coculture Techniques, Proto-Oncogene Proteins c-kit, Receptor Protein-Tyrosine Kinases, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.